



# Pharmacy and Therapeutics Committee

## Meeting Agenda

**Thursday, May 21, 2020**

**7:00 a.m. to 8:45 a.m.**

**Google Hangouts Meet**

Persons who wish to address the P&T Committee may contact Bryan Larson at ([bslarson@utah.gov](mailto:bslarson@utah.gov)) prior to the meeting, or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints.

### **Remote meetings during COVID 19**

The May P&T Committee meeting will be held remotely.

To join Google Hangouts Meet by phone: dial (781) 342-1136. When prompted, enter the following PIN: 250 067 695#.

To Join via Google Hangout Meet online: <https://meet.google.com/hej-yhvk-ues?hs=122>

**\*\*Note that remote attendees will be muted and may not provide public comment without prior written approval.**

- 1) Call to order ..... McKay Robinson, PharmD, Chair
  - a) Announce Quorum
- 2) Welcome and Introductions ..... McKay Robinson, PharmD, Chair
  - a) Review and Approval of Minutes
  - b) Housekeeping
    - i) Updates to PDL format ..... Bryan Larson, PharmD
- 3) DUR Board Update ..... Mohit Bhakta, PharmD
- 4) Accountable Care Organization (ACO) Update: Report on Methodologies for Preferred Drug List Development
  - a) Health Choice.....Richard Ferguson, MD
  - b) HealthyU .....Laura Britton, PharmD
  - c) Molina ..... Heidi Goodrich, PharmD
  - d) SelectHealth ..... Cody Ball, PharmD
- 5) Review
  - a) Cystic Fibrosis Gene Therapies ..... Lauren Heath, PharmD
    - i) elxacaftor/tezacaftor/ivacaftor, ivacaftor, lumacaftor/ivacaftor, tezacaftor/ivacaftor
  - b) Primary Children's Cystic Fibrosis Care Center .....Jeff Zobell, PharmD
  - c) Public Comment
    - i) Vertex.....Lisa Allen, PhD
  - d) Committee Discussion/Questions
  - e) Committee Action

Individuals with questions about accessibility or requesting special accommodations for this meeting should contact Bryan Larson at [bslarson@utah.gov](mailto:bslarson@utah.gov) or (801) 538-6149.



# Pharmacy and Therapeutics Committee

## Meeting Agenda

6) Next Meeting Thursday, June 18, 2020 Topic: Abortive Treatments for Migraines

7) Adjourned ..... McKay Robinson, PharmD, Chair

The foundation documents used for most reviews are prepared by the University of Utah, College of Pharmacy, and are posted on the P&T Committee website after the meeting. Manufacturers wishing to submit any additional materials they would like reviewed as part of the process to:

Dr. Joanne LaFleur  
College of Pharmacy  
30 South 2000 East  
SLC, UT 84112-5820

All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible), unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.

### **Tentative Upcoming Pharmacy & Therapeutics Committee Schedule**

Month	Topic	Agents
18 Jun 2020	Abortive Treatments for Migraines	<i>CGRP antagonists: rimegepant, ubrogepant</i> <i>Triptans: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan</i> <i>Triptan-like agents: lasmiditan</i> <i>Misc: butalbital combination products, butorphanol (nasal), dihydroergotamine, ergotamine, diclofenac (powder for oral solution), triptan combination products</i>
17 Sep 2020	Biological Treatments for Asthma	<i>benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab</i>
19 Nov 2020	TBD	

**Please note: all topics are tentative and subject to change.**

Individuals with questions about accessibility or requesting special accommodations for this meeting should contact Bryan Larson at [bslarson@utah.gov](mailto:bslarson@utah.gov) or (801) 538-6149.